Scd | Jotup

GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease

Retrieved on:

星期四, 六月 25, 2020

Medical specialties, Branches of biology, Health in Africa, Hematopathology, RTT, Sickle cell disease, Medicine, Scd, Stearoyl-CoA desaturase-1

For the second year, the ACCEL program has funded innovative programs that have the potential to deliver high-quality healthcare to people living with SCD.

Key Points:

For the second year, the ACCEL program has funded innovative programs that have the potential to deliver high-quality healthcare to people living with SCD.
Individuals living with sickle cell disease face significant challenges every day, including accessing quality healthcare in their communities.
We selected this years grant recipients based on their potential to make an outsized difference on improving access to care for patients.
Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress

Retrieved on:

星期五, 六月 12, 2020

Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Medical specialties, Biology, Health in Africa, Hematopathology, RTT, Sickle cell disease, Gene therapy, Scd, Crizanlizumab, HGB-206, LentiGlobin for Sickle Cell Disease, bluebird bio, Inc.

These data are being presented at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress.

Key Points:

These data are being presented at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress.
Vaso-occlusive crises (VOCs) are the painful, life-threatening episodes that are the primary clinical manifestation of sickle cell disease.
LentiGlobin for sickle cell disease is an investigational gene therapy being studied as a potential treatment for SCD.
bluebird bios clinical development program for LentiGlobin for SCD includes the ongoing Phase 1/2 HGB-206 study and the ongoing Phase 3 HGB-210 study.

GBT Announces New Employment Inducement Grants

Retrieved on:

星期五, 四月 3, 2020

Proteins, Branches of biology, Selectins, Sickle cell disease, Scd, Stearoyl-CoA desaturase-1, E-selectin, P-selectin

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Key Points:

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease.

GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease

Retrieved on:

星期四, 二月 20, 2020

Medical specialties, Health in Africa, Hematopathology, RTT, Sickle cell disease, Branches of biology, Accel, Scd, Medicine

In 2020, the ACCEL program will fund up to five proposals, providing a grant of up to $50,000 each.

Key Points:

In 2020, the ACCEL program will fund up to five proposals, providing a grant of up to $50,000 each.
We created the ACCEL program to help committed members of the sickle cell community address these very real challenges.
GBT launched ACCEL in February 2019 and provided more than $200,000 in grant funding to U.S.-based nonprofit organizations serving patients with SCD and their families.
Submitted proposals will be reviewed by a panel of GBT and external stakeholders with expertise in the issues affecting people with SCD.

bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

Retrieved on:

星期六, 十二月 7, 2019

bluebird bio, Inc. (Nasdaq: BLUE) announced new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for sickle cell disease (SCD), including additional patients treated in the study and updated data for those previously reported.

Key Points:

bluebird bio, Inc. (Nasdaq: BLUE) announced new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for sickle cell disease (SCD), including additional patients treated in the study and updated data for those previously reported.
LentiGlobin for SCD was designed to add functional copies of a modified form of the -globin gene (A-T87Q-globin gene) into a patients own hematopoietic (blood) stem cells (HSCs).
LentiGlobin for sickle cell disease is an investigational gene therapy being studied as a potential treatment for SCD.
bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-303) for people who have participated in bluebird bio-sponsored clinical studies of LentiGlobin for SCD.

Sickle Cell Disease (SCD) Epidemiology Forecast to 2028: Focus on Turkey, Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina

Retrieved on:

星期四, 十一月 14, 2019

Health in Africa, RTT, Hematopathology, Sickle cell disease, Branches of biology, Medical specialties, Medicine, Epidemiology, Scd

Sickle Cell Disease (SCD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SCD in the 7 Emerging Markets (EM) i.e., Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina.

Key Points:

Sickle Cell Disease (SCD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SCD in the 7 Emerging Markets (EM) i.e., Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina.
The Sickle Cell Disease epidemiology report gives the thorough understanding of the SCD by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Sickle Cell Disease in 7 EM, diagnosed prevalence of Sickle Cell Disease in 7 EM) scenario of Sickle Cell Disease(SCD) in the 7EM covering Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina from 2017-2028.
A detailed review of global historical and forecasted Sickle Cell Disease epidemiology is included in the report, covering drug all 7 EM.

GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Retrieved on:

星期二, 九月 3, 2019

Health, Articles, Sickle-cell disease, Health in Africa, Voxelotor, Sickle cell disease, Scd, Sickle Cell Disease Association of America, American Society of Hematology, Stearoyl-CoA desaturase-1, Therapy, Biopharmaceutical

Taking place during National Sickle Cell Awareness Month, the SCD Therapeutics Conference will highlight the latest medical advances and future trends in the treatment of patients with SCD.

Key Points:

Taking place during National Sickle Cell Awareness Month, the SCD Therapeutics Conference will highlight the latest medical advances and future trends in the treatment of patients with SCD.
The Conference will also feature updates from the American Society of Hematology Research Collaboratives SCD Clinical Trials Network and the Sickle Cell Community Consortium, as well as presentations from biopharmaceutical industry leaders.
We are honored to host, in partnership with the Sickle Cell Disease Association of America, the annual SCD Therapeutics Conference for the third year in a row, as it will bring together patient advocates, opinion leaders and clinical experts, said Ted W. Love, M.D., president and chief executive officer of GBT.
GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy.

Sickle Cell Disease Treatment Market Worth $5.5 Billion by 2023 | CAGR: 14.3%: Grand View Research, Inc.

Retrieved on:

星期四, 十一月 15, 2018

Sickle-cell disease, Medicine, Hematopathology, RTT, Sickle cell disease, Clinical medicine, Health, Crizanlizumab, Scd

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period.

Key Points:

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period.
Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative care.
Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period.
Grand View Research has segmented the global sickle cell disease treatment market based on treatment and country:
Sickle Cell Disease Treatment Outlook (Revenue, USD Million, 2017 - 2023)